Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 3

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3Breast Neoplasms, Male 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × INDUSTRY × HER2 peptide (369-377) × Clear all
NCT02297698 2023-12-12

HER3+

Cancer Insight, LLC

Phase 2 Completed
100 enrolled 11 charts
Breast

Breast Neoplasms

NCT01570036 2020-12-02

Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax

Cancer Insight, LLC

Phase 2 Completed
275 enrolled 23 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT01479244 2017-02-27

PRESENT

Galena Biopharma, Inc.

Phase 3 Completed
758 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡